Becton, Dickinson and Company (BDX.VI)
| Previous close | 216.50 |
| Open | 213.80 |
| Bid | 209.90 x N/A |
| Ask | 211.70 x N/A |
| Day's range | 212.10 - 213.80 |
| 52-week range | 205.90 - 261.00 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 61.298B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 48.31 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.55 (1.64%) |
| Ex-dividend date | 10 Jun 2024 |
| 1y target est | N/A |
- PR Newswire
New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
- PR Newswire
BD Announces Dates for Third Quarter and Fourth Quarter Fiscal 2024 Earnings Webcasts
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates:
- PR Newswire
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.
